RSV001 / GSK, ReiThera - LARVOL DELTA

Enhanced thermostability of a gorilla-derived adenoviral (GRAd) vector via E4 region chimerism (ESGCT 2024) - "ReiThera has developed a COVID-19 vaccine based on a gorilla adenoviral vector (GRAd-COV2)...In addition, the backbone b2 provide a more thermostable product, a property linked to the possibility of storing formulated vaccine lots at 2-8°C, which is extremely beneficial for transport and storage in different countries worldwide. These important characteristics support the use of this backbone for the Phase I clinical trial for GRAdHIVNE1."

Infectious Disease • Novel Coronavirus Disease

GRAd as vaccine platform for COVID-19, HIV, and global health (ESGCT 2024) - "GRAd-COV2, a GRAd-based COVID-19 vaccine, has been the first product based on this platform technology, tested in humans and demonstrated to induce a potent and broad CD8+ and Th1-skewed CD4+ response, associated to a good safety profile and elevated productivity...This innovative approach underscores GRAd’s potential as a versatile and potent vaccine platform for addressing global health challenges. This work has been funded by the Bill and Melinda Gates Foundation (ReiThera grants INV-031044, INV-059646; Ragon Institute grant INV-008696)."

Clinical • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8

Novel adenovirus vaccine vectors lacking binding to the thrombosis associated Platelet Factor 4 protein (ESGCT 2024) - "The Ad34-based vaccine vector also induced anti-spike antibody responses, although at lower levels than those elicited by the parental Ad5 vector. Taken together, we document important advantages of novel PF4-non-binding adenovirus vectors for vaccine delivery, raising expectations for safer vector platforms with decreased risk of VITT in prophylactic as well as therapeutic applications."

Cardiovascular • Gene Therapies • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Thrombocytopenia • Thrombosis • CD4 • CD8

Mycobacterium Tuberculosis polyprotein mRNA vaccines designed to augment protein sorting enhance immunogenicity and protection in preclinical studies (ESGCT 2024) - "Analysis of T cell subsets and cytokine profiles is currently underway. Two priority vaccine candidates have been selected to advance to Phase 1 clinical trials and are currently in the product development pipeline."

Preclinical • Infectious Disease • Respiratory Diseases • Tuberculosis • CD4 • CFP • IFNG • IL2 • TNFA

A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease (ESGCT 2024) - "Sponsored By ReiThera"

Preclinical • Infectious Disease

Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications (ESGCT 2024) - "Sponsored By ReiThera"

Clinical • Infectious Disease

Formulation of mRNA sequences in bio-renewable lipid nanoparticles to counter infection with Mycobacterium tuberculosis and other pathogens (ESGCT 2024) - "Sponsored By ReiThera"

Infectious Disease • Respiratory Diseases • Tuberculosis

SESSION 3c: Infectious Diseases / Vaccines (ESGCT 2024) - "Sponsored By ReiThera"

Infectious Disease

CRISPRa system to improve lab-scale production of rAAV (ESGCT 2024) - "AAV-treated EDMD1 myoblasts will be then evaluated by genomic analyses to detect the correction of the first codon and potential by-stander effects, as well as restoration of emerin expression by immunofluorescence. These data will provide evidences about the clinical relevance of an optimized lab-scale rAAV production."

Gene Therapies • Muscular Dystrophy • EMD • HSF1

Increased AAV Yield: From Screen to Scale Up to Cost Savings Using Viral Sensitizer (VSE TM ) Technology (ASGCT 2025) - "Ultimately, this data underscores the broad applicability of Virica's VSEs as an innovative, economically feasible solution for improved, scalable viral vector production. Disease Focus of Abstract:None"

HEOR • Gene Therapies • Infectious Disease

Enhanced Thermostability of a Gorilla-derived Adenoviral (GRAd) vector via E4 region chimerism (ASGCT 2025) - "ReiThera has developed a COVID-19 vaccine based on a gorilla adenoviral vector (GRAd-COV2)...These important characteristics support the use of this backbone for the Phase I clinical trial for GRAdHIVNE1. Disease Focus of Abstract:None"

Infectious Disease • Novel Coronavirus Disease

GRAd as Vaccine Platform for COVID-19 and HIV (ASGCT 2025) - "GRAd-COV2, a GRAd-based COVID-19 vaccine, has been the first product based on this platform technology, tested in humans and demonstrated to induce a potent and broad CD8 and Th1-skewed CD4 response, associated to a good safety profile and elevated productivity...This innovative approach underscores GRAd's potential as a versatile and potent vaccine platform for addressing global health challenges. Disease Focus of Abstract:HIV"

Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • CD4 • CD8

Intensified Production Process for Gorilla Adenoviral Vector GRAd: Yield, Purity, Potency and Stability Results (ASGCT 2023) - "Adenoviral vectors derived from simian adenovirus and more specifically from great apes have been studied in millions of human subjects using vaccine vectors encoding different antigens (relevant to Ebola, malaria, hepatitis C, human immunodeficiency virus [HIV], respiratory syncytial virus [RSV] and COVID-19) have shown that this vaccine platforms are safe and can generate potent, durable, and high-quality T cell and antibody (Ab) responses.Reithera has developed a COVID-19 vaccine using a novel gorilla adenovirus classified into species C. This adenovirus isolated from a captive animal was converted into a replication-defective adenoviral vector generating GRAd-COV2 vaccine...In addition, the final product was demonstrated to be stable at +2-8°C for more than one year. In conclusion, this novel GRAd vector is an attractive vaccine platform suitable for development and production of high-throughput vaccines against pathogens or diseases requiring the generation of..."

Viral vector • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Malaria • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Suspension-Based Adenovirus Production Process Development and Scale-Up in scale-TM Fixed-Bed Bioreactors (ASGCT 2023) - "Further scale-up to 200m2 scale using scale-XTM nitro bioreactor, never performed for adenovirus production, led to a large-scale consistent cell growth and titer of 9.00 x 104 VP/cell (total yield 3.53x1016 VPs). As a conclusion, the scale-XTM family provided an efficient way to make process transfer on small scale, proved straightforward scalability and process optimization on the middle scale, and yielded high titer adenovirus manufacturing on a large scale."

Infectious Disease

Intensified Production Process for Gorilla Adenoviral Vector, GRAd: Yield, Purity, Potency and Stability Results (ASGCT 2023) - "The technology for viral-vector production is validated.The technology can be used for other vector types, like AAV, especially if a systemic gene therapy requires a large amount of vector production."

Viral vector • Gene Therapies • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Malaria • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

ReiThera: ReiThera's Technology Development and CDMO capabilities (ASGCT 2023) - "Sponsored By ReiThera"

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults. (PubMed, Clin Exp Immunol) - "Cohorts of healthy younger adults (18-50yrs) and healthy older adults (60-75yrs) were immunized intramuscularly or intranasally with an adenovirus-vectored RSV vaccine (PanAd3-RSV) as a prime dose and boosted with PanAd3-RSV or a poxvirus-vectored vaccine (MVA-RSV) encoding the same insert...Intranasally primed participants showed greater numbers of DEGS on boosting than intramuscularly primed participants. The most highly enriched biological processes related to DEGs after both prime and boost vaccination were type-1 interferon related pathways, lymphocytic and humoral immune responses."

Journal • Viral vector • Immunology • Respiratory Syncytial Virus Infections

[VIRTUAL] ReiThera (BIO 2021) - "ReiThara bases its core capacity in a state-of-the-art facility including stirred-tank bioreactors supporting a working volume at the scale of 200L, 1000L and 2000L for production in suspension and fixed bed bioreactors for adherent growth of the cell substrate. ReiThera is welcome to meet company interested in exploring the possibility of performing process development and GMP production at ReiThe"

Infectious Disease • Novel Coronavirus Disease